Literature DB >> 15823507

Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.

Shuwen Liu1, Hong Lu, Qian Zhao, Yuxian He, Jinkui Niu, Asim K Debnath, Shuguang Wu, Shibo Jiang.   

Abstract

Theaflavin derivatives and catechin derivatives are the major polyphenols in black tea and green tea, respectively. Several tea polyphenols, especially those with galloyl moiety, can inhibit HIV-1 replication with multiple mechanisms of action. Here we showed that the theaflavin derivatives had more potent anti-HIV-1 activity than catechin derivatives. These tea polyphenols could inhibit HIV-1 entry into target cells by blocking HIV-1 envelope glycoprotein-mediated membrane fusion. The fusion inhibitory activity of the tea polyphenols was correlated with their ability to block the formation of the gp41 six-helix bundle, a fusion-active core conformation. Computer-aided molecular docking analyses indicate that these tea polyphenols, theaflavin-3,3'-digallate (TF3) as an example, may bind to the highly conserved hydrophobic pocket on the surface of the central trimeric coiled coil formed by the N-terminal heptad repeats of gp41. These results indicate that tea, especially black tea, may be used as a source of anti-HIV agents and theaflavin derivatives may be applied as lead compounds for developing HIV-1 entry inhibitors targeting gp41.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823507     DOI: 10.1016/j.bbagen.2005.02.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  44 in total

1.  Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus.

Authors:  Charles E Isaacs; Weimin Xu; George Merz; Sharon Hillier; Lisa Rohan; Guang Y Wen
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

2.  A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.

Authors:  Lifeng Cai; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

Review 3.  Amphipathic properties of HIV-1 gp41 fusion inhibitors.

Authors:  Miriam Gochin; Guangyan Zhou
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

4.  Antileishmanial Activity of Lignans, Neolignans, and Other Plant Phenols.

Authors:  Jiří Pospíšil; Daniela Konrádová; Miroslav Strnad
Journal:  Prog Chem Org Nat Prod       Date:  2021

Review 5.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

6.  Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Authors:  Dirk Roymans; Hendrik L De Bondt; Eric Arnoult; Peggy Geluykens; Tom Gevers; Marcia Van Ginderen; Nick Verheyen; Hidong Kim; Rudy Willebrords; Jean-François Bonfanti; Wouter Bruinzeel; Maxwell D Cummings; Herman van Vlijmen; Koen Andries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

7.  Theaflavin-3,3'-digallate and lactic acid combinations reduce herpes simplex virus infectivity.

Authors:  Charles E Isaacs; Weimin Xu
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

8.  Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.

Authors:  Yong Wang; Hong Lu; Qiang Zhu; Shibo Jiang; Yun Liao
Journal:  Bioorg Med Chem Lett       Date:  2009-11-05       Impact factor: 2.823

9.  The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection.

Authors:  Ilona Hauber; Heinrich Hohenberg; Barbara Holstermann; Werner Hunstein; Joachim Hauber
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

10.  Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy.

Authors:  Christina L Nance; Edward B Siwak; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.